You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

ANDROGEL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Androgel, and what generic alternatives are available?

Androgel is a drug marketed by Besins Hlthcare and is included in two NDAs. There are eight patents protecting this drug.

This drug has forty-five patent family members in twenty-nine countries.

The generic ingredient in ANDROGEL is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Androgel

A generic version of ANDROGEL was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ANDROGEL?
  • What are the global sales for ANDROGEL?
  • What is Average Wholesale Price for ANDROGEL?
Drug patent expirations by year for ANDROGEL
Drug Prices for ANDROGEL

See drug prices for ANDROGEL

Drug Sales Revenue Trends for ANDROGEL

See drug sales revenues for ANDROGEL

Recent Clinical Trials for ANDROGEL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
VA Office of Research and DevelopmentPhase 2
University Medical Center GroningenN/A
National Heart, Lung, and Blood Institute (NHLBI)Phase 4

See all ANDROGEL clinical trials

Pharmacology for ANDROGEL
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists

US Patents and Regulatory Information for ANDROGEL

ANDROGEL is protected by eight US patents.

Patents protecting ANDROGEL

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Testosterone gel and method of use
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Besins Hlthcare ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-002 Sep 7, 2012 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ANDROGEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Besins Hlthcare ANDROGEL testosterone GEL, METERED;TRANSDERMAL 021015-003 Sep 26, 2003 ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 021015-001 Feb 28, 2000 ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL;TRANSDERMAL 022309-003 Sep 7, 2012 ⤷  Sign Up ⤷  Sign Up
Besins Hlthcare ANDROGEL testosterone GEL, METERED;TRANSDERMAL 021015-003 Sep 26, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ANDROGEL

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Warner Chilcott UK Ltd. Intrinsa testosterone EMEA/H/C/000634
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
Warner Chilcott  Deutschland GmbH Livensa testosterone EMEA/H/C/000630
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ANDROGEL

See the table below for patents covering ANDROGEL around the world.

Country Patent Number Title Estimated Expiration
South Africa 200407403 Androgen pharmaceutical composition and method for treating depression ⤷  Sign Up
South Africa 200301686 Method of increasing testosterone and related steroid concentrations in women. ⤷  Sign Up
Ukraine 87627 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ В ВИДЕ ТЕСТОСТЕРОНОВОГО ГЕЛЯ И ЕЕ ИСПОЛЬЗОВАНИЕ ПРИ ЛЕЧЕНИИ ГИПОГОНАДИЗМА У МУЖЧИН;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ У ВИГЛЯДІ ТЕСТОСТЕРОНОВОГО ГЕЛЮ ТА ЙОГО ЗАСТОСУВАННЯ ПРИ ЛІКУВАННІ ГІПОГОНАДИЗМУ В ЧОЛОВІКІВ (TESTOSTERONE GEL FORMULATION AND ITS USE FOR TREATING HYPOGONADISM IN MAN) ⤷  Sign Up
Eurasian Patent Organization 009815 УПАКОВКА С ДОЗИРОВАННОЙ ФОРМОЙ ТЕСТОСТЕРОНОВОГО ГЕЛЯ ДЛЯ ЛЕЧЕНИЯ ГИПОГОНАДИЗМА И СПОСОБ ЕЁ ПОЛУЧЕНИЯ (TESTOSTERONE GEL IN UNIT DOSE PACKET FOR TREATING HYPOGONADISM AND METHOD FOR PREPARING THEREOF) ⤷  Sign Up
South Korea 20050074896 ⤷  Sign Up
Norway 20082170 ⤷  Sign Up
Norway 20200014 Forbedret testosterongel og fremgangsmåte til anvendelse ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.